Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 3/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620983 | 0.86 | GRM5 (0.58) | ATRGRM5PIM1PIM3PIM2 | |
| SCHEMBL1802383 | 0.83 | PIM1 (0.62) | ATRGRM5PIM1PIM3PIM2 | |
| SCHEMBL14059993 | 0.81 | ATR (0.76) | ATRGRM5PRKDCCYP3A4PRKCI | |
| SCHEMBL31387927 | 0.81 | ATR (0.76) | ATRGRM5PRKDCCYP3A4PRKCI | |
| SCHEMBL6035375 | 0.80 | GSK3B (0.60) | ATRGRM5PIM1PIM3PIM2 | |
| SCHEMBL11906844 | 0.79 | PIM2 (0.76) | ATRPIM1PIM3PIM2GSK3B | |
| SCHEMBL411951 | 0.77 | ATR (0.75) | ATRGRM5PRKDCCYP3A4GSK3B | |
| SCHEMBL11909197 | 0.77 | GRM5 (0.50) | ATRGRM5PIM1PIM3PIM2 | |
| SCHEMBL20581634 | 0.77 | PIM2 (0.61) | ATRPIM1PIM3PIM2CYP3A4 | |
| SCHEMBL6035019 | 0.77 | GSK3B (0.61) | ATRGRM5PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118275-A1 | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| US-20110118275-A1 | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| WO-2011059388-A1 | OXAZOLO[4,5-C]PYRIDINE SUBSTITUTED PYRAZINE | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059388-A1 | OXAZOLO[4,5-C]PYRIDINE SUBSTITUTED PYRAZINE | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118275-A1 | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118275-A1 | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE | OXA1L, MC2R, CYP3A5 | ATR 2235/4885GRM5 68/4885PIM1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.